All In Biotech

Drug Trial Radar · NCT07279740

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alzheimer Society of Canada; Sunnybrook Research Institute; Brain Canada
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia

Conditions

  • Alzheimer s Disease
  • Alzheimer Dementia (AD)
  • Alzheimer Dementia
  • Alzheimer Disease
  • Apathy
  • Apathy in Dementia

Interventions

  • intermittent theta burst stimulation (iTBS)Device

    iTBS is a form of repetitive transcranial magnetic simulation (rTMS), a non-invasive form of brain stimulation.

  • Methylphenidate (MPH)Drug

    Participants will be on methylphenidate clinically prior to the trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Neuropsychiatric Inventory-Apathy (NPI-A) scoreTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.